Philips divests non-core FIMI for greater focus
This article was originally published in Clinica
Philips has divested its FIMI medical display business to Belgian firm Barco, in a bid to focus on its core healthcare platforms. Barco, which specialises in display technology, will pay €19m ($28.3m) in cash for FIMI with an additional earn-out of €10m to be paid over the next five years. The FIMI business manufactures endoscopy, surgical mobile point-of-care and patient monitoring displays, and generated revenues of €42m in 2008. Kortrijk-based Barco will add FIMI to its portfolio of diagnostic, surgical and mammography displays. The deal allows Philips to focus its efforts on expanding the areas of its medtech business that it deems to have high-growth potential, including home healthcare solutions and imaging systems.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals